Study of 124I-NM404 in Advanced Solid Malignancies

University of Wisconsin, Madison12 enrolled

Overview

The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.

124I-NM404 is a new investigational agent being developed to better identify local tumors and cancerous tumors using imaging technologies such as positron emission tomography (PET) scans. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. 124I-NM404 is only taken up by the cancer cells, not the normal cells. Compared to traditional methods such as CT (computed tomography) or MRI (Magnetic resonance imaging), 124I-NM404 may help physicians more accurately see and evaluate cancerous tumors. This agent has been safely studied in animals and a limited number of human patients with lung cancer. This study is being done to determine the best dose to use and to fully evaluate the images that result from using this new agent.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer

Interventions

124I-NM404DRUG

124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of advanced solid malignancy. * Allowed tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head \& neck cancer * Disease must be at least 1cm in diameter * Brain metastasis must be stable for at least one month. * ECOG performance status 0-2 * Anticipated survival less than 5 years, as per the treating physician Exclusion Criteria: * Skin lesions only * Chemotherapy or radiotherapy within 1 week * Residual toxicities of grade 2 or greater from prior therapy * Adequate organ function as per specified laboratory parameter * Platelet count \> or = to 75,000/uL

Locations (1)

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Optimal Imaging Parameters

To determine the optimal imaging parameters (dose, acquisition time, imaging time post injection, normal organ and tumor dosimetry) of 124I-NM404 in subjects with advanced solid malignancies with one of the following tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head \& neck cancer

Time frame: 2 years

Secondary Outcomes

Adverse events

Number and grade of adverse events attributable to 124I-NM-404

Time frame: 2 years

PET comparison

compare 18F-FDG PET to 124I-NM404 PET

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.